Pipeline
- Overview
  - Stenoparib
  - External Programs
- Clinical Trials
Medical Laboratory
Technology
- The DRP^® Method
- Scientific Publications
About Us
Investors
- Overview
- News
- Stock Info
- Financials
- Governance
- Resources
- Presentations
Contact
- General Inquires
Careers
- Join Allarity

Pipeline
- Overview
  - Stenoparib
  - External Programs
- Clinical Trials
Medical Laboratory
Technology
- The DRP^® Method
- Scientific Publications
About Us
Investors
- Overview
- News
- Stock Info
- Financials
- Governance
- Resources
- Presentations
Contact
- General Inquires
Careers
- Join Allarity

4/A [Amend] – Statement of changes in beneficial ownership of securities

Filed: 2026-04-30 AccNo: 0001213900-26-050133 Size: 5 KB

Post navigation

← Previous SEC filing

Next SEC filing →

Pipeline
Overview
– Stenoparib – External Programs
– Clinical Trials

Technology
The DRP^® Platform
Scientific Publications

About Us
Overview
Leadership
Board of Directors
SAB
Partnering

Investors
Overview
News
Stock Info
Financials
Governance Resources
Presentations

Newsroom
News
Media Contact

Contact
General Inquires

Careers
Join Allarity

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Social Media Policy

Cookie Policy

United States:
123 E Tarpon Ave
Tarpon Springs, FL 34689
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562